We have recently shown that CETSA (Cellular Thermal Shift Assay), a recently described method that allows for the rapid and simple assessment of drug target engagement in a cellular context [81,82,83], is useful in predicting crizotinib sensitivity in ALK-carrying cancer cells [32]. This evidence concerns the gene ALK and cancer.